A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]
© Collantes et al; licensee BioMed Central Ltd. 2002
Received: 23 January 2002
Accepted: 22 May 2002
Published: 22 May 2002
Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA).
Double-blind, randomized, placebo and active comparator-controlled, 12-week study conducted at 67 sites in 28 countries. Eligible patients were chronic NSAID users who demonstrated a clinical worsening of arthritis upon withdrawal of prestudy NSAIDs. Patients received either placebo, etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1 allocation ratio). Primary efficacy measures included direct assessment of arthritis by counts of tender and swollen joints, and patient and investigator global assessments of disease activity. Key secondary measures included the Stanford Health Assessment Questionnaire, patient global assessment of pain, and the percentage of patients who achieved ACR20 responder criteria response (a composite of pain, inflammation, function, and global assessments). Tolerability was assessed by adverse events and routine laboratory evaluations.
1171 patients were screened, 891 patients were randomized (N = 357 for placebo, N = 353 for etoricoxib, and N = 181 for naproxen), and 687 completed 12 weeks of treatment (N = 242 for placebo, N = 294 for etoricoxib, and N = 151 for naproxen). Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p<0.05). Treatment responses were similar between the etoricoxib and naproxen groups for all endpoints. The percentage of patients who achieved ACR20 responder criteria response was 41% in the placebo group, 59% in the etoricoxib group, and 58% in the naproxen group. Etoricoxib and naproxen were both generally well tolerated.
In this study, etoricoxib 90 mg once daily was more effective than placebo and similar in efficacy to naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg was generally well tolerated in RA patients.
Rheumatoid arthritis (RA) is a highly inflammatory, chronic, systemic disease which affects connective tissue and involves multiple joints. The traditional symptomatic therapy for many inflammatory diseases, including RA, has been nonsteroidal antiinflammatory agents (NSAIDs) [1, 2]. In RA, NSAIDs are often used in conjunction with disease modifying antirheumatism drugs such as methotrexate, or may be taken as monotherapy for symptomatic relief [1, 2]. While NSAIDs are effective in controlling the joint pain and swelling in RA, their side effect profile limits their use in some patients. In particular, the potential for gastrointestinal toxicity with traditional nonselective NSAIDs can be a significant limitation of their use . Gastrointestinal bleeding, ulceration, and perforation, are the most common serious adverse events associated with NSAIDs and often lead to discontinuation of NSAID therapy as well as expensive treatment for the gastropathic symptoms themselves . Continuous exposure to high doses of NSAIDs, as well as frequent concomitant use of steroids, puts RA patients at particular risk for gastrointestinal-associated adverse events [3, 5].
The new generation of NSAID treatments which selectively inhibit cyclooxygenase-2 (COX-2) while sparing COX-1 offer an alternative treatment option for many patients with RA and other inflammatory disorders . Previous studies have shown that the selective COX-2 inhibitors, rofecoxib and celecoxib, are effective and well-tolerated treatments for RA, with decreased gastrointestinal toxicity versus non-selective NSAIDs [6–8]. A recent clinical trial conducted in the United States found that the new, highly selective COX-2 inhibitor, etoricoxib (90 mg), was effective in the treatment of RA and also suggested that this dose of etoricoxib might be more effective than a 1000-mg dose of the non-selective NSAID naproxen . The present study conducted at sites throughout the world further investigated the clinical profile of etoricoxib 90 mg in RA patients.
Materials and Methods
This randomized, double-blind, parallel-group 12-week study was conducted at 67 sites in 28 countries, including the U.S. (see acknowledgments for list of countries and investigators). Patients were enrolled between November 1999 and June 2000. Each site received the approval of its Ethics Review Committee or Institutional Review Board to perform the study. Written informed consent was obtained from every patient evaluated. Patients who discontinued the study due to lack of efficacy or who completed the 12-week, placebo-controlled trial were offered the opportunity to enter a blinded active comparator-controlled 40-week extension. The data from the 40-week, active comparator-controlled extension will be reported separately.
Eligible patients were age ≥18 years and fulfilled diagnostic criteria for RA as specified by the 1987 revised criteria of the American Rheumatism Association . In addition, patients were required to have an established diagnosis of RA for at least 6 months prior to entering the study, a history of a clinical response to NSAID therapy, and to have been taking NSAID therapy on a regular basis (at least 25 of the past 30 days). Patients with a history of angina or congestive heart failure, with symptoms that occurred at rest or minimal activity, and/or who had a history of myocardial infarction, coronary angioplasty, or coronary bypass within the past year were excluded as were those with a history of stroke, transient ischemic attack or hepatitis in the previous two years. Patients with uncontrolled hypertension at screening were also excluded. Patients with any medical condition which, in the opinion of the investigator, could have confounded study results or caused undue risk to the patient (e.g., comorbid conditions for which NSAIDs are contraindicated) were also excluded. Three hemoccult screens were performed prior to allocation and patients with any evidence of active gastrointestinal bleeding were excluded. At randomization, patients could not be taking concomitant warfarin, ticlopidine, clopidrogel or digoxin. Patients on stable doses of disease modifying therapy (except TNF inhibitors) and low doses of corticosteroids (prednisone <10 mg daily) were allowed to continue therapy. Patients were permitted to take low dose aspirin (up to 100 mg/day), but in practice <3% patients used aspirin during the study.
Patients were assessed for disease activity and those who met entry criteria were asked to discontinue their current NSAID use and return for evaluation when symptoms worsened (disease flare). At re-evaluation for study inclusion, patients were required to have ≥ 6 tender joints, ≥ 3 swollen joints, and at least a 20% increase in the number of tender and swollen joints compared with screening visit assessments. In addition, investigators must have rated patients as "fair," "poor," or "very poor" on the investigator global assessment of disease activity, and noted either of the following: 1) morning stiffness for ≥45 minutes plus increased duration of morning stiffness by at least 15 minutes since screening visit evaluation, or 2) a score of >40 mm on patient global assessment of pain (a 100-mm visual analog scale [VAS]) and at least a 10-mm increase in patient assessment of pain over that reported at screening visit evaluation.
Patients meeting the above flare criteria were randomized to placebo, etoricoxib 90 mg once daily, or naproxen 500 mg twice daily in a 2:2:1 allocation ratio. Randomization was stratified by use or non-use of low-dose corticosteroids. Efficacy evaluations were performed at baseline and at weeks 2, 4, 8, and 12. Efficacy assessments included all components of the American College of Rheumatology (ACR) core set of outcome measures: tender joint count, swollen joint count, patient global assessment of disease activity, investigator global assessment of disease activity, Stanford Health Assessment Questionnaire (HAQ) of disability (an assessment of the patient's mobility and ability to carry out activities of daily living), patient global assessment of pain, and C-reactive protein level [2, 10]. Four endpoints were specified as primary: tender joint count (total 68 joints), and swollen joint count (total 66 joints), patient global assessment of disease activity (100-mm VAS; 0 = "very well", 100 = "very poor"), investigator global assessment of disease activity (0 to 4 Likert scale; 0 = "very well", 1 = "well", 2 = "fair", 3 = "poor", 4 = "very poor"). Key secondary measures included patient global assessment of pain (100-mm VAS; 0 = "no pain", 100 = "extreme pain"), HAQ disability score (the average score of 9 disability questions, each graded on a 0 to 3 Likert scale: 0 = "without any difficulty", 1 = "with some difficulty", 2 = "with much difficulty", 3 = "unable to do"), and the proportion of patients who met the ACR20 criteria for a clinically relevant response (a composite criteria requiring 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core measures)  and who completed the study (ACR20-completers). The percentage of patients who discontinued due to lack of efficacy were also measured. For completeness, we also looked at the percentage of patients meeting ACR20 criteria regardless of whether or not they completed the study.
Laboratory assessments (serum chemistry, complete blood count, urinalysis) were performed at baseline and at weeks 2, 4, 8 and 12. Clinical and laboratory adverse events were recorded throughout the study. Investigators rated the intensity, relation to study drug (possibly, probably, or definitely drug-related; probably not or definitely not drug-related), and seriousness (includes events which are life threatening, result in hospitalization, or cause permanent incapacity, or other significant event) of adverse events. All potential upper gastrointestinal perforations, ulcers and bleeds (PUBs) and all potential cardiovascular thrombotic events (including cardiac, peripheral vascular and cerebrovascular events) were reviewed by independent blinded adjudication committees, who determined if they were confirmed events according to pre-specified case definitions (confirmed adjudicated events) .
The primary analytic method for evaluating efficacy was to compare treatment groups using the time-weighted average change from baseline across 12 weeks for the 7 ACR core measures. The rates at 12 weeks for ACR20-completers, and the cumulative rates over 12 weeks for discontinuations due to lack of efficacy were also compared between treatment groups. Pair-wise comparisons were based on the difference between mean responses, except for C-reactive protein level, where the mean ratio was analyzed via log transformation. A modified intent-to-treat approach was employed – all patients with baseline and at least 1 post-baseline measurement were included in the analysis. Analysis of covariance (including terms for baseline covariate, stratum [corticosteroid use], and treatment) was used for all efficacy variables except ACR20-completers, and discontinuation rates due to lack of efficacy. The percentages of patients meeting ACR20-completers criteria were compared between treatment groups using the Cochran-Mantel-Haenszel test with corticosteroid use as a stratification factor, and Fisher's Exact test was used to make between-treatment comparisons of the discontinuation rates due to lack of efficacy. The analysis of serum C-reactive protein was based on the log of on-treatment value over baseline value. Plots of mean changes from baseline at each time point for the 4 primary endpoints were made to assess the maintenance of therapeutic effect for etoricoxib and naproxen. A last-observation-carried-forward method was used for these longitudinal graphs, but not for the time-weighted average changes shown in the table of results.
Tolerability was evaluated by tabulation of all clinical and laboratory safety parameters, including adverse events. Active treatments were compared with placebo using Fisher's exact test for the percentages of patients with any drug-related clinical adverse event, with any serious clinical adverse event, or who discontinued due to a clinical adverse event. Evaluations of data regarding safety were made by various means, including an examination of patients exceeding predefined limits for laboratory values of interest (e.g., consecutive decreases in hemoglobin and hematocrit, increased aminotransferase values, or increases in serum creatinine), common events associated with NSAIDs or COX-2 inhibitors (e.g., hypertension and lower extremity edema), and percentages of patients discontinuing due to adverse events.
Baseline patient characteristics
Etoricoxib 90 mg
Naproxen 1000 mg
(N = 357)
(N = 353)
(N = 181)
Mean age [yrs] (SD)
Mean duration of rheumatoid arthritis [yrs] (SD)
% rheumatoid factor-positive
% in ARA functional class:
% taking rheumatoid arthritis medications:
Disease modifying antirheumatic drugs
Mean patient global assessment of disease activity (100 mm visual analog scale) ‡ (SD)
Mean investigator global assessment of disease activity (0 to 4 scale) ‡ (SD)
Mean number of tender joints (of 68) ‡ (SD)
Mean number of swollen joints (of 66) ‡ (SD)
Mean (95% confidence interval) efficacy differences between treatments over 12 weeks
Etoricoxib vs placebo
Naproxen vs placebo
Etoricoxib vs naproxen
Patient global assessment of disease activity (100 mmVAS) ‡
0.09 (-3.61, 3.79)
Investigator global assessment of disease activity (0–4 scale) ‡
0.08 (-0.08, 0.24)
Tender joint count (total 68 joints) ‡
-0.26 (-2.05, 1.54)
Swollen joint count (total 66 joints) ‡
-0.03 (-1.24, 1.17)
Patient global assessment of pain (100 mm VAS) ‡
0.84 (-2.96, 4.63)
Health Assessment Questionnaire disability (0–3 scale) ‡
0.08 (0.00, 0.17)
Serum C-reactive protein (ratio between treatments)
1.11† (1.00, 1.23)
0.99 (0.87, 1.13)
1.12 (0.99, 1.27)
ACR20 responder criteria (%)
17.83* (10.55, 25.12)
16.68* (7.80, 25.57)
1.15 (-7.74, 10.03)
Discontinuation due to lack of efficacy (%)
1.97 (-3.67, 7.61)
Summary of safety data
Etoricoxib 90 mg
Naproxen 1000 mg
(N = 357)
(N = 353)
(N = 181)
Number of patients:
With any drug-related clinical adverse event
82 (23.2) †
With any serious clinical adverse event‡
Discontinued due to clinical adverse event
Most common adverse events and events of interest in evaluating COX-inhibitors
Etoricoxib 90 mg
Naproxen 1000 mg
(N = 357)
(N = 353)
(N = 181)
Most Common Adverse Events†
Upper Respiratory Infection
Urinary Tract Infection
Events of Interest in Evaluating COX Inhibitors
Gastrointestinal (GI) Adverse Events
GI Nuisance Symptoms‡
Renovascular Adverse Events
Lower Extremity Edema (LEE)
Discontinuations due to LEE
Congestive Heart Failure
Discontinuations due to hypertension
This multinational study confirmed findings from a replicate study  that a 90-mg daily dose of the COX-2 selective inhibitor, etoricoxib, was more effective than placebo for treating patients with RA. The treatment effects of etoricoxib occurred by the first assessment (at 2 weeks) and were sustained throughout the 12 weeks of the study.
Etoricoxib showed similar efficacy to a high dose of the non-selective NSAID naproxen, supporting results from studies with other selective COX-2 inhibitors in RA which also showed similar efficacy to non-selective NSAIDs [7, 8]. The results differed from those in the replicate study of etoricoxib in RA  which found that etoricoxib was more effective than naproxen. The reason for the difference in results between the two studies is unclear since the studies had identical designs, including entry criteria, doses of study medication, and outcome measures. However, although patient enrollment criteria were identical, more patients in the present study were using concomitant corticosteroids (approximately 57% versus 32%) and disease modifying antirheumatic drugs, including methotrexate (approximately 82% versus 68%). It is conceivable that the increased concomitant RA medication use may have obscured the ability to detect small, but perhaps meaningful differences between active treatments. Interestingly, in this study as compared to the replicate etoricoxib RA study , the placebo response rate was higher (ACR20-responders were 40.9% in the current study versus 20.8% in the replicate study) and the discontinuations due to lack of efficacy were lower in the placebo group (25.2% in the current study vs 54.5% in the replicate study), and this may also have influenced the results. Although unproven, other potential explanations may relate to the fact that the present study was conducted largely outside the United States and the previous study inside the United States . Therefore, differences in underlying disease characteristics and/or cultural differences in perceptions of efficacy may have also contributed to the difference in the results. Others have reported different findings for RA studies with similar designs which were conducted in the United States versus other countries. Serum C-reactive protein levels were noted to be elevated compared to placebo in the etoricoxib group. This was not observed in other etoricoxib RA studies [19, 9]; in one study no difference was seen from placebo , and in the other study a lowering in serum C-reactive protein was observed . It is generally not believed that changes in serum C-reactive protein are substantially influenced by NSAID treatment. Therefore, this was not felt to represent a clinically meaningful finding.
Etoricoxib was generally well tolerated by the patients in this study, consistent with results from prior clinical trials of etoricoxib for RA and other indications [9, 11–13]. There was a significantly higher number of patients with drug-related clinical adverse events for etoricoxib versus placebo. However, the difference was small and should be interpreted with caution since more patients on placebo discontinued early (primarily due to lack of efficacy) and therefore had less chance of experiencing an adverse event. The findings may therefore overestimate adverse event rates for the active treatments compared with placebo.
Particular attention was paid to the typical NSAID-related renal effects of edema and hypertension since data with both selective COX-2 inhibitors and non-selective NSAIDs have suggested that they have an effect on renal physiology [14, 15]. Etoricoxib and naproxen showed a small increase in hypertension adverse events compared with placebo. Mean changes in blood pressure among the treatment groups was small, and both etoricoxib and naproxen treatment groups showed only small increases in mean systolic blood pressure compared to baseline. Among patients who had hypertension adverse events on etoricoxib, no patient discontinued from the study. The incidences of lower extremity edema adverse events for etoricoxib were similar to placebo and no patient treated with etoricoxib discontinued as a result.
The main proposed advantage for selective COX-2 inhibitors is reduced gastrointestinal toxicity. However, a thorough and adequate assessment of this can only be made either in very large long-term trials or pooled analyses because of the relatively low incidence of clinically significant gastrointestinal PUBs [6, 16]. In fact, only one confirmed PUB was reported in the present study.
It has also been suggested [6, 17, 18] that the use of selective COX-2 agents may be associated with a higher incidence of cardiovascular thrombotic events than naproxen (a potent and sustained inhibitor of platelet aggregation at therapeutic doses). As with upper GI clinical events (PUBs), these events are rare and conclusive data can only be adequately amassed in large data sets. The incidence of confirmed cardiovascular thrombotic events in the present study was low (3 events), therefore no meaningful conclusions about the overall cardiovascular safety of etoricoxib can be determined from this single study.
In summary, etoricoxib 90 mg once daily provided clinically meaningful improvements of the signs and symptoms of RA that were superior to those of placebo and comparable to those of naproxen 500 mg twice daily. Etoricoxib 90 mg was generally well tolerated in this study. These data provide further support for the addition of etoricoxib to the available therapeutic options in the management of RA patients.
Primary investigators in the Etoricoxib Rheumatoid Arthritis Study Group were: T Adamson (USA), S Aslanidis (Greece), A Badilla (Costa Rica), C Barfield (USA), A Beaulieu (Canada), M Bell (Canada), M Berliner (Germany), TA Bermudez (Spain), L Bidula (USA), K Boki (Greece), H Broell (Austria), A Cabral (Mexico), J Calvo Catala (Spain), N Casas (Colombia), D Ching (New Zealand), C Codreanu (Romania), B Colaco (UK), E Collantes (Spain), B Combe (France), J. Forstot (USA), S Garcia Perez (Spain), E George (UK), C Glave (Peru), J Granados (Spain), M Gutierrez (USA), P Hanrahan (Australia), F Hasler (Switzerland), J Higashida (USA), G Ho (USA), P Howard (USA), JA Jover Jover (Spain), J Kalden (Germany), T Karger (Germany), J Karsh (Canada), J Kekow (Germany), DR Koh (Singapore), M Kohen (USA), M Kos-Golja (Slovenia), KW Lee (Hong Kong), H Marker (USA), M Martinez-Lavin (Mexico), A Mathieu (Italy), T McCarthy (Canada), L McLean (New Zealand), F Mielke (Germany), J Molina (Colombia), M Nahir (Israel), G Nesher (Israel), JM Padrino Martinez (Spain), M Peshimam (USA), A Posada (Venezuela), R Rau (Germany), O Rillo (Argentina), C Rojas (Chile), P Sandall (USA), B Snyder (USA), H Sorensen (Germany), B Souza (Brazil), M Tikly (South Africa), JC Torres Alonso (Spain), O Troum (USA), J Udell (USA), G Valentini (Italy), E VanDuuren (South Africa), P Vecchio (Australia), A Venalis (Lithuania), CA Von Muhlen (Brazil), M Yaron (Israel), H Yazici (Turkey), F Zaidi (USA)
- American College of Rheumatology Ad Hoc Committee on clinical guidelines: Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 723-731.View ArticleGoogle Scholar
- American College of Rheumatology Ad Hoc Committee on clinical guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 1996, 39: 713-722.View ArticleGoogle Scholar
- Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999, 340: 1888-1899. 10.1056/NEJM199906173402407.View ArticlePubMedGoogle Scholar
- Fries JF, Williams CA, Bloch DA, Michel BA: Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991, 91: 213-222.View ArticlePubMedGoogle Scholar
- van Riel PLCM, Wijnands MJH, van de Putte LBA: Evaluation and management of active inflammatory disease. In: Rheumatology. Edited by: Klippel JH, Dieppe PA, Arnett FC. 1998, London: Mosby, 14.1-14.2. 2ndGoogle Scholar
- Bombardier C, Laine L, Reicin A, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med. 2000, 343: 1520-1528. 10.1056/NEJM200011233432103.View ArticlePubMedGoogle Scholar
- Schnitzer TJ, Truitt K, Fleischmann R, et al: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clinical Therapeutics. 1999, 21: 1688-1702. 10.1016/S0149-2918(99)80048-4.View ArticlePubMedGoogle Scholar
- Emery P, Zeidler H, Kvien KT, et al: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet. 1999, 354: 2106-2111. 10.1016/S0140-6736(99)02332-6.View ArticlePubMedGoogle Scholar
- Matsumoto A, Melian A, Mandel DR, et al: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatology. 2002,Google Scholar
- Felson DT, Anderson JJ, Boers M, et al: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 727-735.View ArticlePubMedGoogle Scholar
- Malmstrom K, Shahane A, Fricke JR, Ehrich E: MK –0663–an investigational COX-2 inhibitor: the effect in acute pain using the dental-impaction model. Arthritis Rheum. 2000, 43: S299 [Abstract]-Google Scholar
- Gottesdiener K, Schnitzer T, Fisher C, et al: MK-663, a specific COX-2 inhibitor for treatment of osteoarthritis (OA) of the knee. Arthritis Rheum. 1999, 42: S144 [Abstract]-Google Scholar
- Gottesdiener K, Schnitzer T, Fisher C, et al: Treatment with MK-663, a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthritis (OA) of the knee that was sustained over three months. Ann Rheum Dis. 2000, 59: 133 [Abstract]-Google Scholar
- Brater DC, Harris C, Redfern JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am J Nephrol. 2001, 21: 1-15. 10.1159/000046212.View ArticlePubMedGoogle Scholar
- Murray MD, Brater DC: Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol. 1993, 32: 435-465.View ArticleGoogle Scholar
- Langman MJ, Jensen DM, Watson DJ, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999, 282: 1929-1933. 10.1001/jama.282.20.1929.View ArticlePubMedGoogle Scholar
- Catella-Lawson F, Crofford LJ: Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001, 110: 28S-32S. 10.1016/S0002-9343(00)00683-5.View ArticlePubMedGoogle Scholar
- Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective cox-2 inhibitors. JAMA. 2001, 286: 954-959. 10.1001/jama.286.8.954.View ArticlePubMedGoogle Scholar
- Curtis SP, Maldonado-Cocco J, Lozada B, et al: Characterization of the clinically effective dose range of MK-0663, a COX-2 selective inhibitor, in the treatment of rheumatoid arthritis. Arthritis Rheum. 2000, 43: S226 [Abstract]-View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2296/3/10/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.